A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Clinical Trial ID NCT01101594

PubWeight™ 6.29^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01101594

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.	Blood	2010	1.53
2	CD74: a new candidate target for the immunotherapy of B-cell neoplasms.	Clin Cancer Res	2007	1.51
3	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
4	CD74 is expressed by multiple myeloma and is a promising target for therapy.	Clin Cancer Res	2004	1.25
5	Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.	Clin Cancer Res	2005	1.22
6	Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.	Clin Cancer Res	2003	1.00
7	Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma.	Cancer Res	1989	0.99
8	Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.	Leukemia	2015	0.92
9	Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.	Clin Dev Immunol	2012	0.88
10	Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.	Clin Cancer Res	2009	0.87
11	Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.	Expert Opin Investig Drugs	2009	0.86
12	Advances in the treatment of hematologic malignancies using immunoconjugates.	Blood	2014	0.83
13	Development of Novel Immunotherapies for Multiple Myeloma.	Int J Mol Sci	2016	0.82
14	The development of potential antibody-based therapies for myeloma.	Blood Rev	2014	0.81
15	Involvement of macrophage migration inhibitory factor in cancer and novel therapeutic targets.	Oncol Lett	2016	0.76